NCT04418206

Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 950 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and indicates that a subject is infected with SARS-CoV-2. This test can be in about 30% of false negative cases, it does not allow to date the infection, nor to predict the asymptomatic, mild, moderate or severe evolution of the disease. In terms of public health, we need 1/ to better understand the chronology of the immune response to the virus in the general population and in contacts of index cases; 2/ To know which characteristics of the immune response are protective of future reinfections. Finally, in symptomatic subjects, we need biomarkers that predict the evolutionary mode of the disease (moderate vs. severe form).

Conditions

• Covid 19

Interventions

Type	Name	Description
OTHER	patients COVID 19	Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)

Timeline

• Start date: 2020-06-01
• Primary completion: 2022-02-10
• Completion: 2022-07-19
• First posted: 2020-06-05
• Last updated: 2026-03-24

Locations

4 sites across 1 country: France